Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-FAPI Therapy in Advanced Solid Tumors
IRCT20210612051548N2Phase 2Completed
- Sponsor
- Bushehr University of Medical Sciences
- Start
- Sep 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 177Lu-DOTA-FAPI in brain neoplasm, thyroid cancer, gastrointestinal stromal tumor (GIST) and 6 more, sponsored by Bushehr University of Medical Sciences. Started Sep 2021; status: completed.
02
Drugs
177Lu-DOTA-FAPI
03
Conditions
brain neoplasmthyroid cancergastrointestinal stromal tumor (GIST)bronchial carcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20210612051548N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210612051548N2.